Pegaspargase

B-Cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)protein_peptidePhase 3Active

BB

70/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 68/ 100
Competitive Position: 73/ 100

Competitive context

135 Active assets in the B-Cell Acute Lymphoblastic Leukemia cohort.

Asset / Sponsor	Phase	Rating
Etoposide University of Washington	Phase 3	BBB
Vincristine Sulfate City of Hope Medical Center	Phase 3	BB
Crisantaspase City of Hope Medical Center	Phase 3	BB
Dasatinib National Cancer Institute (NCI)	Phase 3	BB
Nivestim University of Washington	Phase 3	BB

View all 50 →

Same molecule, other indications

Pegaspargase is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant

A

Indicative · Phase 3

80 / 100

extranodal nasal NK/T cell lymphomaActive

BBB

Indicative · Phase 4

76 / 100

non-Hodgkin lymphomaDormant

BBB

Indicative · Phase 4

75 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.